DEPOSIT AGREEMENT by and among INNATE PHARMA S.A. and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [date], [year]Deposit Agreement • October 4th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • Delaware
DEPOSIT AGREEMENT, dated as of ___________, 20__, by and among (i) INNATE PHARMA S.A., a company organized under the laws of France, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
SALES AGREEMENTSales Agreement • February 6th, 2024 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
AMENDMENT TO PROPERTY LEASE AGREEMENT by the Company “SOGEBAIL” in favor of the Company “INNATE PHARMA”Property Lease Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances)
Maître Roselyne BOTELLA , a notary in the “SCP THIBIERGE ET ASSOCIES, Notaries, members of a private professional partnership holding a Notarial Office,” with headquarters in PARIS (eighth district), 9 rue d’Astorg,
JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENTJoint Research, Development, Option and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
Exclusive License AgreementExclusive License Agreement • April 4th, 2024 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), entered into as of March 31, 2023 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a company incorporated under the laws of the State of Delaware (“Takeda”), and Innate Pharma S.A., a company organized and existing under the laws of the country of France (“Innate”). Innate and Takeda are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201Co-Development and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
THIS SECOND AMENDMENT TO THE CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201 (this “Second Amendment”) is made and entered into as of July 26, 2019 (the “Amendment Effective Date”), by and between MedImmune Limited, a company organized under the laws of England and Wales (“MedImmune”) and Innate Pharma S.A, a company organized under the laws of France (“Innate”). MedImmune and Innate are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.
STATE GUARANTEED LOAN (Free translation) By and between BNP PARIBAS, a société anonyme with a share capital of 2.499.597.122 euros, whose registered office is at PARIS (75009),16, Boulevard des Italiens, registration number 662 042 449, RCS PARIS -...State Guaranteed Loan • April 4th, 2022 • Innate Pharma SA • Biological products, (no disgnostic substances)
STATE GUARANTEED LOAN (Free translation) By and between THE BANK SOCIETE GENERALE, Société Anonyme with a share capital of 1 066 714 367,50 euros, registered under unique registration number 552 120 222 RCS Paris, with head office located at PARIS...State Guaranteed Loan • April 4th, 2022 • Innate Pharma SA • Biological products, (no disgnostic substances)
LICENSE AGREEMENT -between- MEDIMMUNE LIMITED -and- INNATE PHARMA S.A. LICENSE AGREEMENTLicense Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
WHEREAS, MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC (AstraZeneca PLC and its Affiliates being “AstraZeneca”). MedImmune and its Affiliates have experience in the research, development, manufacturing and commercialization of pharmaceutical products worldwide, including treatments for cancer both using small molecules and large molecules.
●] American Depositary Shares Representing [●] Ordinary Shares (Par Value €0.05 Per Share) INNATE PHARMA S.A. UNDERWRITING AGREEMENTUnderwriting Agreement • October 4th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
This letter is being delivered to you in connection with the offering by Innate Pharma S.A. (the “Company”) of (i) ordinary shares, par value €0.05 per share (the “Ordinary Shares”) and (ii) Ordinary Shares to be delivered in the form of American Depositary Shares (“ADSs”), of the Company and the lock-up letter dated ____, 2019 (the “Lock-Up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 2019, with respect to [____ Ordinary Shares (the “Lock-Up Shares”)] [____ ADSs (the “Lock-Up ADSs”)].
INNATE PHARMA S.A. $75,000,000 Ordinary Shares (Par Value €0.05 Per Share) Represented by American Depositary Shares SALES AGREEMENTSales Agreement • May 3rd, 2022 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
Innate Pharma S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Marseille under number 424 365 336 (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
ContractCollaboration and Option Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
